3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sarcoma
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Temozolomide
7
Bevacizumab
4
sargramostim
2
rindopepimut
2
Radiotherapy
2
Radiation
2
Oncolytic Virotherapy
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Cyclophosphamide
2
1-methyltryptophan
2
ridaforolimus
1
prinomastat
1
pembrolizumab
1
pamiparib
1
marizomib
1
interferon gamma-1b
1
enzastaurin
1
depatuxizumab mafodotin
1
capmatinib
1
Sucrose
1
Spermine Synthase
1
Radiosurgery
1
Procarbazine
1
ONC206
1
NVP-BKM120
1
Leflunomide
1
Interferon-gamma
1
Interferon-beta
1
Immunotherapy
1
Fentanyl
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gliosarcoma
×
Interferon-gamma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled